• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[合并心血管疾病患者的新型冠状病毒肺炎:墨西哥城第四次疫情期间的一系列病例]

[COVID-19 in patients with pre-existing cardiovascular disease: a series of cases during the fourth epidemiologic wave in Mexico City].

作者信息

Mendoza-González Celso A, Antonio-Villa Neftalí E, Contreras-Alanis Mireya B, Fernández-Sandoval María F, Castillo-Macías Jimena, Sandoval-Colin Daniel E, Vera-Chávez Jacobo S, Quiroz-Martínez Víctor A, Del Valle-Zamora Karina

机构信息

Cardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.

出版信息

Arch Cardiol Mex. 2024 Jul 26;94(4):480-487. doi: 10.24875/ACM.23000259.

DOI:10.24875/ACM.23000259
PMID:39058955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12148541/
Abstract

OBJECTIVE

SARS-CoV-2 infection induces an immune response that causes excessive inflammation damaging cardiac tissue and vascular endothelium. The objective of this study is to review a series of cases of hospitalized patients with pre-existing cardiac disease to describe the clinical behavior and highlight the low frequency of morbidity and mortality.

METHOD

Retrospective study of 17 patients with a confirmed diagnosis of COVID-19 by polymerase chain reaction test or antigen test, a history of cardiovascular disease with or without comorbidities, and a history of at least one dose of the vaccine for COVID-19, during the period between December 30, 2021 and March 17, 2022 at the Ignacio Chávez National Institute of Cardiology in Mexico City.

RESULTS

The most frequent cardiac pathology was acute myocardial infarction (31.25%) and the most common arrhythmia was atrial fibrillation (25%). The median number of days of hospital stay was 10 days (interquartile range: 4-14). Regarding the outcomes, 94% of the patients were discharged due to clinical improvement, and only one patient died during his hospitalization.

CONCLUSIONS

It is crucial to continue investigating SARS-CoV-2 effects in patients pre-existing heart disease and in those with persistent symptoms after infection. This will allow the development of more effective strategies for the treatment and prevention of cardiovascular complications associated with COVID-19.

摘要

目的

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染引发免疫反应,导致过度炎症,损害心脏组织和血管内皮。本研究的目的是回顾一系列患有基础心脏病的住院患者病例,以描述其临床行为,并强调低发病率和死亡率。

方法

对2021年12月30日至2022年3月17日期间在墨西哥城伊格纳西奥·查韦斯国家心脏病学研究所确诊感染新冠病毒(COVID-19)的17例患者进行回顾性研究,这些患者有心血管疾病病史,有或无合并症,且有至少一剂COVID-19疫苗接种史。

结果

最常见的心脏病理是急性心肌梗死(31.25%),最常见的心律失常是心房颤动(25%)。住院天数中位数为10天(四分位间距:4 - 14天)。关于结局,94%的患者因临床症状改善而出院,住院期间仅有1例患者死亡。

结论

继续研究SARS-CoV-2对患有基础心脏病的患者以及感染后有持续症状患者的影响至关重要。这将有助于制定更有效的策略来治疗和预防与COVID-19相关的心血管并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c97/12148541/c928b3630ed2/10125AMEX244-ACM-94-480-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c97/12148541/c928b3630ed2/10125AMEX244-ACM-94-480-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c97/12148541/c928b3630ed2/10125AMEX244-ACM-94-480-g001.jpg

相似文献

1
[COVID-19 in patients with pre-existing cardiovascular disease: a series of cases during the fourth epidemiologic wave in Mexico City].[合并心血管疾病患者的新型冠状病毒肺炎:墨西哥城第四次疫情期间的一系列病例]
Arch Cardiol Mex. 2024 Jul 26;94(4):480-487. doi: 10.24875/ACM.23000259.
2
Cardiac complications in patients hospitalised with COVID-19.COVID-19 住院患者的心脏并发症。
Eur Heart J Acute Cardiovasc Care. 2020 Dec;9(8):817-823. doi: 10.1177/2048872620974605. Epub 2020 Nov 21.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
Prevalence and outcomes of atrial fibrillation in patients hospitalized with COVID-19.COVID-19 住院患者心房颤动的患病率和结局。
Curr Med Res Opin. 2024 Sep;40(9):1477-1481. doi: 10.1080/03007995.2024.2378179. Epub 2024 Jul 26.
5
A Pragmatic Study of Cardiovascular Disease During Long-Term COVID-19.长期新冠病毒感染期间心血管疾病的实用研究
Am J Med. 2025 Mar;138(3):532-540.e1. doi: 10.1016/j.amjmed.2024.03.011. Epub 2024 Mar 26.
6
Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients.718365 例 COVID-19 患者中心肌炎和心包炎的患病率及临床结局。
Eur J Clin Invest. 2021 Nov;51(11):e13679. doi: 10.1111/eci.13679. Epub 2021 Sep 18.
7
Clinical behavior of COVID-19 in a reference public hospital in Mexico City during SARS-CoV-2 epidemiological waves.在墨西哥城一家参考公立医院中,新冠病毒(SARS-CoV-2)流行期间2019冠状病毒病(COVID-19)的临床行为
J Infect Dev Ctries. 2025 Jan 31;19(1):17-21. doi: 10.3855/jidc.20076.
8
Severe acute respiratory syndrome coronavirus 2 infection in hematopoietic stem cell transplant recipients in Mexico City.墨西哥城造血干细胞移植受者中严重急性呼吸综合征冠状病毒 2 感染。
Transpl Infect Dis. 2024 Aug;26(4):e14274. doi: 10.1111/tid.14274. Epub 2024 Apr 4.
9
Burden of cardiovascular disease on coronavirus disease 2019 hospitalizations in the USA.美国心血管疾病对 2019 冠状病毒病住院患者的负担。
Coron Artery Dis. 2024 Nov 1;35(7):584-589. doi: 10.1097/MCA.0000000000001390. Epub 2024 May 27.
10
Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City.墨西哥城住院 COVID-19 患者的神经表现。
PLoS One. 2021 Apr 8;16(4):e0247433. doi: 10.1371/journal.pone.0247433. eCollection 2021.

本文引用的文献

1
Impact of COVID-19 on Cardiovascular Disease.新冠疫情对心血管疾病的影响。
Viruses. 2023 Feb 11;15(2):508. doi: 10.3390/v15020508.
2
The heart and SARS-CoV-2.心脏与新型冠状病毒2019(SARS-CoV-2)
Med Clin (Engl Ed). 2022 Nov 11;159(9):440-446. doi: 10.1016/j.medcle.2022.10.001. Epub 2022 Oct 14.
3
Cardiovascular complications in the Post-Acute COVID-19 syndrome (PACS).急性 COVID-19 综合征(PACS)后的心血管并发症。
Int J Cardiol Heart Vasc. 2022 Mar 28;40:101012. doi: 10.1016/j.ijcha.2022.101012. eCollection 2022 Jun.
4
COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.COVID-19 疫苗混打:概念、效果和疑虑。
J Med Virol. 2022 Apr;94(4):1294-1299. doi: 10.1002/jmv.27463. Epub 2021 Nov 30.
5
Epidemiology of hospitalized patients with COVID-19 in a tertiary care hospital.COVID-19 住院患者的流行病学。
Gac Med Mex. 2021;157(3):237-244. doi: 10.24875/GMM.M21000552.
6
COVID-19 and Cardiovascular Disease: a Global Perspective.新型冠状病毒肺炎与心血管疾病:全球视角。
Curr Cardiol Rep. 2021 Aug 19;23(10):135. doi: 10.1007/s11886-021-01566-4.
7
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.COVID-19 疫苗研发进展:病毒、疫苗和变体与疗效、有效性和逃逸。
Nat Rev Immunol. 2021 Oct;21(10):626-636. doi: 10.1038/s41577-021-00592-1. Epub 2021 Aug 9.
8
Covid and Cardiovascular Diseases: Direct and Indirect Damages and Future Perspective.新冠病毒与心血管疾病:直接与间接损害及未来展望
High Blood Press Cardiovasc Prev. 2021 Sep;28(5):439-445. doi: 10.1007/s40292-021-00464-8. Epub 2021 Jun 26.
9
Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment.COVID-19 患者的心血管疾病:从心血管病理学到治疗的证据。
Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):273-282. doi: 10.1093/abbs/gmaa176.
10
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.COVID-19 与心血管系统:对风险评估、诊断和治疗选择的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687. doi: 10.1093/cvr/cvaa106.